Recommended Guidelines for Lymphoma Management
Hodgkin Lymphoma
Staging and Risk Assessment
All patients require contrast-enhanced CT of neck, chest, and abdomen; baseline PET-CT is now the standard when available 1. Bone marrow biopsy is no longer needed if PET-CT is performed 1. Staging laparotomy is obsolete 2.
Mandatory laboratory work includes:
- Complete blood count, ESR, LDH, alkaline phosphatase, liver enzymes, albumin, TSH
- Screening for HBV, HCV, and HIV 1
- Cardiac and pulmonary function tests before treatment
- Reproductive counseling with sperm banking or oocyte cryopreservation for patients of reproductive age 1
Risk stratification uses Ann Arbor classification with three categories:
- Limited stage: Stage I-II without risk factors
- Intermediate stage: Stage I-II with ≥1 risk factors (large mediastinal mass >1/3 chest diameter, extranodal disease, elevated ESR, ≥3 nodal areas)
- Advanced stage: Stage III-IV or IIB with specific risk factors 2
Treatment of Classical Hodgkin Lymphoma
Limited-Stage Disease
Standard treatment is 2-3 cycles of ABVD followed by 30 Gy involved-site radiotherapy (ISRT) 1. This combined modality approach is superior to radiotherapy alone. ISRT has replaced involved-field radiotherapy to reduce late toxicity 1.
Intermediate-Stage Disease
Four cycles of ABVD followed by 30 Gy ISRT is the standard of care 1. For patients ≤60 years eligible for intensive treatment, 2 cycles of BEACOPPescalated followed by 2 cycles of ABVD and 30 Gy ISRT can be offered 1.
Critical caveat: Patients with positive interim PET after 2 cycles of ABVD should switch to 2 cycles of BEACOPPescalated before ISRT 1.
Advanced-Stage Disease
Patients ≤60 years receive either 6 cycles of ABVD or 4-6 cycles of BEACOPPescalated, optionally followed by localized radiotherapy 1.
PET-guided treatment modifications:
- After 2 cycles of ABVD with negative interim PET: omit bleomycin in cycles 3-6, especially in elderly or those at risk for lung toxicity 1
- Positive interim PET after 2 cycles of ABVD: switch to BEACOPPescalated 1
- After 2 cycles of BEACOPPescalated: PET-negative patients need only 2 more cycles; PET-positive patients need 4 more cycles 1
- Radiotherapy restricted to PET-positive residual lymphoma ≥2.5 cm after chemotherapy 1
Important restriction: BEACOPP should NOT be given to patients >60 years due to excessive toxicity 1. Use 6-8 cycles of ABVD instead, discontinuing bleomycin after cycle 2 1.
Relapsed/Refractory Disease
High-dose chemotherapy followed by autologous stem cell transplantation is the treatment of choice for most patients 1. For patients failing ASCT, brentuximab vedotin or anti-PD-1 antibodies (nivolumab, pembrolizumab) are approved options 1.
Follow-Up
Structured surveillance schedule:
- Every 3 months for first 6 months
- Every 6 months until year 4
- Annually thereafter 1
Surveillance imaging is NOT indicated unless clinical symptoms develop 1. One CT scan to confirm remission status is sufficient. Annual TSH monitoring if neck was irradiated 1.
Diffuse Large B-Cell Lymphoma (DLBCL)
Staging and Risk Assessment
PET-CT is now the gold standard for staging DLBCL 3. If unavailable, contrast-enhanced CT of neck, chest, and abdomen is required 4.
Mandatory workup:
- Complete blood count, LDH, uric acid
- HIV, HBV (HBs antigen, anti-HBs, anti-HBc), and HCV screening 3
- Protein electrophoresis 3
Bone marrow biopsy is no longer required when PET-CT demonstrates bone/marrow involvement indicating advanced disease, but is appropriate if PET is negative and results would change treatment, especially when shortened chemotherapy cycles are proposed 3.
Genetic testing recommendations:
- MYC and BCL2 rearrangements using fluorescence in situ hybridization in newly diagnosed and relapsed patients treated with curative intent 3
- "Double-hit" or "triple-hit" lymphomas (MYC + BCL2 ± BCL6 rearrangements) have poor prognosis 3
Treatment
Young Low-Risk Patients (Age-Adjusted IPI ≤1)
Six to eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) every 21 days is the standard 4. Consolidation radiotherapy to initial sites has no proven benefit 4.
Young High-Risk Patients (Age-Adjusted IPI >1)
Six to eight cycles of R-CHOP every 14 days or dose-intensive regimens like R-ACVBP can be used 4. Radiotherapy to bulky disease sites has no proven benefit 4.
Patients Aged 60-80 Years
Eight cycles of R-CHOP every 21 days is the standard 4. If given every 14 days, 6 cycles of CHOP with 8 cycles of rituximab are sufficient 4. Consolidation radiotherapy in localized disease has no proven benefit 4.
Patients >80 Years
R-CHOP can be used in fit patients until age 80. For very elderly patients, rituximab with attenuated chemotherapy can induce complete remission in selected cases 4.
CNS Prophylaxis
Consider in patients with high-intermediate or high-risk IPI, especially those with >1 extranodal site or elevated LDH 4. However, the evidence base remains limited.
Response Assessment
End-of-treatment PET-CT is more accurate than CT alone, eliminating the "complete response unconfirmed" category 5. Use the 5-point Deauville scale: scores 1-2 represent complete metabolic response 5.
Indolent B-Cell Lymphomas
The provided evidence focuses primarily on aggressive lymphomas. For indolent lymphomas, treatment approaches vary significantly by histology and stage, ranging from watchful waiting in asymptomatic patients to rituximab-based immunochemotherapy in symptomatic or advanced disease.
Mantle Cell Lymphoma
Most patients present with disseminated disease requiring systemic treatment 6. Immunochemotherapy has been the mainstay, but recent data suggest adding covalent Bruton tyrosine kinase inhibitors (cBTKi) may substantially improve outcomes 6.
For elderly patients, rituximab-bendamustine remains standard, though this may be challenged by non-chemotherapeutic options like rituximab plus cBTKi 6.
For relapsed/refractory disease, rapidly developing options include:
- CAR-T cell therapy
- Novel BTK targeting agents
- BCL2 inhibitors
- T-cell engagers 6
Primary CNS Lymphoma
MRI is the imaging modality of choice for suspected CNS lymphoma 3. Treatment typically involves high-dose methotrexate-based regimens, as demonstrated in the case report where MRT (methotrexate, rituximab, temozolomide) achieved complete remission 7.
Key Pitfalls to Avoid
- Do not perform bone marrow biopsy in Hodgkin lymphoma if PET-CT is available 1
- Do not give BEACOPP to patients >60 years 1
- Do not continue bleomycin beyond 2 cycles in patients >60 years or those at risk for lung toxicity 1
- Do not perform routine surveillance imaging in asymptomatic patients after achieving remission 1
- Do not reduce chemotherapy doses for hematological toxicity in curative-intent treatment—use growth factors instead 4
- Do not skip HBV screening—reactivation can be fatal during immunochemotherapy 1, 3